Nigeria Launches First Immunotherapy Program for Colorectal Cancer in Sub-Saharan Africa
核心洞察
Nigeria has launched the Innovative Cancer (搜索) Medicine Demonstration Project at National Hospital Abuja (搜索), marking the first time advanced cancer immunotherapy will be administered in a structured feasibility study in Sub-Saharan Africa.
The program provides free nivolumab treatment to 30 patients with metastatic colorectal cancer (搜索), with full costs estimated at over seven billion naira sponsored by international partners including Bristol Myers Squibb (搜索), Roche, and the Parker Institute for Cancer Immunotherapy.
The initiative represents a collaboration between the Federal Government, Clinton Health Access Initiative, and pharmaceutical partners to demonstrate that Nigeria has the infrastructure and expertise to safely deliver advanced cancer (搜索) treatment.
Four patients with metastatic colorectal cancer (搜索) have begun receiving nivolumab at National Hospital Abuja (搜索), marking a historic milestone as Nigeria becomes the first country in Sub-Saharan Africa to administer advanced immunotherapy treatment within a structured feasibility study. The Innovative Cancer (搜索) Medicine (ICM) Demonstration Project represents a groundbreaking collaboration between the Federal Government and international partners to transform cancer care access in Africa.
The initiative brings together the Federal Ministry of Health and Social Welfare (搜索), Clinton Health Access Initiative (CHAI), Parker Institute for Cancer Immunotherapy (PICI), Bristol Myers Squibb (搜索) (BMS), and Roche in an unprecedented partnership. Bristol Myers Squibb is donating all required nivolumab doses, while Roche contributes diagnostic testing reagents and biomarker screening materials.
Breaking Down Cost Barriers
The program addresses the stark reality that a year of nivolumab treatment typically costs over $160,000 per patient—far beyond reach for most Nigerians. Each dose costs approximately ₦9.5 million per treatment cycle, with the full study estimated at over seven billion naira, completely covered by international sponsors.
"There's no cost to the patients," explained Dr. Olufunke Fasawe, Country Director of CHAI. "The Parker Institute has funded CHAI to provide technical assistance to the hospital, and part of that funding also supports the medical team—oncologists, pharmacists, radiation oncologists, and everyone involved. We even provide health insurance for the patients to cover any adverse events, and transportation stipends so that nothing prevents them from completing their treatment."
The comprehensive support extends beyond medication to include screening, testing, biopsy analysis, patient monitoring, laboratory investigations, and supportive therapies—all provided free of charge.
Demonstrating Feasibility, Not Efficacy
Professor Bello Abubakar, Principal Investigator at National Hospital Abuja (搜索), emphasized that this is not a clinical trial but a demonstration project. "This drug has been used globally and approved for use, so we are not testing its efficacy but demonstrating that we can deliver it safely here in our environment," he said.
The study aims to enroll 30 patients with metastatic colorectal cancer (搜索) over 18 months, recruiting from across Nigeria as long as patients can receive treatment at the National Hospital Abuja (搜索). The initiative specifically targets a disease that ranks as the second most common cancer (搜索) among Nigerian men and fourth overall.
Overcoming Regulatory Challenges
The path to implementation faced significant hurdles when Nigeria's regulatory agency NAFDAC initially viewed the initiative as a clinical trial rather than a demonstration project. The breakthrough came through intervention by the former Minister of State for Health, who helped the agency understand that nivolumab wasn't experimental but a proven therapy used worldwide for years.
"The intervention of the former Minister of State for Health—a kidney specialist—was crucial," Dr. Fasawe recalled. "He helped the agency see that nivolumab wasn't experimental anymore. It had been used worldwide for years. This wasn't about testing efficacy; it was about giving Nigerian patients access to a proven and effective therapy."
Building on Established Access Programs
This immunotherapy initiative builds on CHAI's Cancer (搜索) Access Program, launched in 2016 with American Cancer Society funding. Through negotiations with pharmaceutical companies, the program achieved price reductions of more than 50% on 16 essential chemotherapy drugs, including carboplatin, making them accessible across Sub-Saharan Africa.
The National Cancer (搜索) Access Partnership program now includes 24 tertiary hospitals and has served more than 7,000 patients with affordable, quality-assured chemotherapy. Pharmaceutical partners have expanded beyond Pfizer to include AstraZeneca, Sandoz, Janssen, Hetero, and Roche.
Government Commitment and Infrastructure Development
Minister of State for Health and Social Welfare Dr. Iziaq Adekunle Salako described the initiative as reflecting the Tinubu administration's commitment to improving healthcare access through strategic partnerships. The government has approved the largest budget allocation for cancer (搜索) care in Nigeria's history for 2025.
Infrastructure development includes six regional cancer (搜索) treatment centers, with three completed and three more planned by year-end through the National Sovereign Investment Authority. However, significant gaps remain—Nigeria currently has about 11 radiotherapy machines in the public sector with only one or two functional, compared to the estimated need for 200 machines for a population of 200 million.
Long-term Vision for Market Access
The demonstration project serves as a stepping stone toward broader access through policy integration and market shaping. Success could lead to nivolumab inclusion in Nigeria's National Health Insurance scheme and the Cancer (搜索) Health Fund, which supports low-income Nigerians.
"Our long-term work at CHAI is about market shaping—negotiating price reductions so that governments can afford these drugs sustainably," Dr. Fasawe explained. The initiative extends beyond Nigeria, with Uganda also participating, as success in one country can help open doors for the entire region.
Clinical Impact and Future Implications
Nigeria records approximately 6,000 deaths from colorectal cancer (搜索) annually, with around 7,000 new cases estimated each year. While treating 30 patients represents a small fraction of this burden, the program establishes proof of concept for advanced cancer (搜索) care delivery in Nigeria.
Dr. Martin J. Murphy, Chairman and Co-Founder of the Society for Translational Oncology, described the launch as "the dawn of a new era in African medicine," noting that "the most advanced form of cancer (搜索) treatment, using drugs that activate a patient's immune system (搜索) to destroy tumors, is being delivered in a hospital on African soil."
The initiative has generated significant public interest, with many patients writing to inquire about enrollment opportunities. As Dr. Fasawe concluded, "This initiative isn't just about 30 patients. It's about showing that it can be done—that advanced cancer (搜索) care can be delivered safely, ethically, and affordably in Africa. Once we prove that, everything changes."